News | August 21, 2014

Cardiva Financing Will Expand Commercialization of Vascade Vascular Closure Device

Cardiva Medical Inc. Vascade Vascular Closure System Series 3 financing U.S.

August 21, 2014 — Cardiva Medical Inc. said it closed the first two tranches of a $16.5 million Series 3 private equity financing and a $12.5 million senior secured facility with GE Capital. The company will use the proceeds of the Series 3 private equity financing and debt facility to expand commercial efforts for its Vascade vascular closure system in the United States.

Investing in Series 3 private equity financing was a new investor, Canepa Advanced Healthcare Fund L.P., who joined existing investors PTV Sciences, AmKey Ventures and TriVentures II Fund L.P. Paul Enever from Canepa U.S. LLC, which serves as Investment Advisor to Canepa Advanced Healthcare Fund L.P., has joined the Cardiva board of directors.

"We are extremely pleased that Canepa Advanced Healthcare, L.P. has joined Cardiva's current investors in this financing and that Paul Enever has joined our board of directors," said Charles Maroney, CEO. Maroney continued, "With the Series 3 equity financing and GE debt facility, Cardiva now has the financial resources to establish Vascade as a leading extravascular closure technology, which we believe can benefit both patients and healthcare providers in the United States by minimizing complications and associated costs and improving patient care when compared to conventional vascular closure devices."

"Cardiva's product platform offers the potential to transform the vascular closure market by improving both patient safety and comfort," said Paul Enever of Canepa U.S. LLC. Enever continued, "Vascade leverages Cardiva's Catalyst platform, [which] has been utilized effectively in more than 400,000 procedures since its initial launch into the U.S. market in 2007." We are delighted to add Cardiva to our investment portfolio of emerging growth medical device companies that are focused on improving patient outcomes while reducing the cost of medical care."

Cardiva Medical develops and commercializes vascular closure technology designed to help the body heal itself following catheterization. The company's products include Vascade, a next generation extravascular closure system, and Catalyst II and Catalyst III, which are designed to aid manual compression.

Vascade was approved by the U.S. Food and Drug Administration (FDA) in 2013 and approved for CE marking in 2012. Catalyst II and Catalyst III were cleared for marketing by the FDA in 2007 and 2009, respectively.

For more information: www.cardivamedical.com

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters| August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Overlay Init